Skip to content
Home/Companies/Biotech/Oxford Cancer Analytics

Oxford Cancer Analytics

Biotech·UK·Active·4yr hold
Entry
2022
Hold
4yr
Status
Active

Who owns Oxford Cancer Analytics?

Oxford Cancer Analytics is a British Biotech company, currently owned by EKA Ventures since 2022.

Hand-verified · updated 2026-06-30

Open JSON · CC-BY
EKA Ventures
Investor
EKA Ventures
Eka Ventures Fund I · 2021 · Impact

Key facts

HQUK
SectorBiotech
StatusActive

More from Eka Ventures Fund I

Other portfolio companies in the same fund.

32Co
Active
HealthTechUK· 2024
Airhive
Active
ClimateTechUK· 2024
MakeSense
MakeSense
Active
MedTechUK· 2024
XRlabs
XRlabs
Active
MedTechUK· 2024
Axle
Axle
Active
ClimateTechUK· 2023
Isla
Isla
Active
HealthTechUK· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Oxford Cancer Analytics?

Oxford Cancer Analytics is currently owned by EKA Ventures, through Eka Ventures Fund I, since 2022.

When did EKA Ventures acquire Oxford Cancer Analytics?

EKA Ventures acquired Oxford Cancer Analytics in 2022.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue